Catechol-O-methyltransferase is dispensable for vascular protection by estradiol in mouse models of atherosclerosis and neointima formation

Endocrinology

Volumn 152, Issue 12, 2011, Pages 4683-4690

  Wilhelmson, Anna S ^a   Bourghardt Fagman, Johan ^a   Gogos, Joseph A ^b   Fogelstrand, Per ^a   Tivesten, Åsa ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; APOLIPOPROTEIN E; CATECHOL METHYLTRANSFERASE; CHOLESTEROL; ESTRADIOL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; BODY WEIGHT; CAROTID ARTERY; CAROTID ARTERY LIGATION; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG PELLET; ENZYME ACTIVITY; FEMALE; GENOTYPE; GONADECTOMY; HEART PROTECTION; HORMONAL THERAPY; IN VIVO STUDY; LIPID DIET; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SEMINAL VESICLE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UTERUS WEIGHT; VASCULAR PROTECTION; WEIGHT GAIN; WILD TYPE;

ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; CATECHOL O-METHYLTRANSFERASE; ESTRADIOL; FEMALE; MALE; MICE; NEOINTIMA; PROTECTIVE AGENTS;

EID: 82355188223     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1458     Document Type: Article

References (48)

1. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH 2010 Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 95:s1-s66
2. Sullivan Jr TR, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, O'Donnell Jr TF, Mendelsohn ME 1995 Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 96:2482-2488
3. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ 1996 Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 93:10022-10027
4. Elhage R, Arnal JF, Pieraggi MT, Duverger N, Fiévet C, Faye JC, Bayard F 1997 17β-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 17:2679-2684 (Pubitemid 28016008)
5. Marsh MM, Walker VR, Curtiss LK, Banka CL 1999 Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice. J Lipid Res 40:893-900 (Pubitemid 29220530)
6. Xing D, Nozell S, Chen YF, Hage F, Oparil S 2009 Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 29:289-295
7. Brinton EA, Hodis HN, Merriam GR, Harman SM, Naftolin F 2008 Can menopausal hormone therapy prevent coronary heart disease? Trends Endocrinol Metab 19:206-212 (Pubitemid 351997464)
8. Martucci CP, Fishman J 1993 P450 enzymes of estrogen metabolism. Pharmacol Ther 57:237-257 (Pubitemid 23175382)
9. Zhu BT, Conney AH 1998 Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19:1-27 (Pubitemid 28376821)
10. Dubey RK, Tofovic SP, Jackson EK 2004 Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther 308:403-409 (Pubitemid 38134197)
11. Dubey RK, Imthurn B, Jackson EK 2007 2-Methoxyestradiol: a potential treatment for multiple proliferative disorders. Endocrinology 148:4125-4127 (Pubitemid 47295670)
12. Dubey RK, Jackson EK 2009 Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol Metab 20:374-379
13. Mueck AO, Seeger H 2010 2-Methoxyestradiol - biology and mechanism of action. Steroids 75:625-631
14. Liu D, Bachmann KA 1998 An investigation of the relationship between estrogen, estrogen metabolites and blood cholesterol levels in ovariectomized rats. J Pharmacol Exp Ther 286:561-568 (Pubitemid 28318034)
15. Dubey RK, Jackson EK 2001 Cardiovascular protective effects of 17beta-estradiol metabolites. J Appl Physiol 91:1868-1883 (Pubitemid 32900383)
16. Sibonga JD, Lotinun S, Evans GL, Pribluda VS, Green SJ, Turner RT 2003 Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology 144:785-792 (Pubitemid 36262845)
17. Bourghardt J, Bergström G, Krettek A, Sjö berg S, Borén J, Tivesten A 2007 The endogenous estradiol metabolite 2-methoxyestradiol reduces atherosclerotic lesion formation in female apolipoprotein E-deficient mice. Endocrinology 148:4128-4132
18. Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B, Dubey RK 2006 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res 99:266-274 (Pubitemid 44174934)
19. Bonacasa B, Sanchez ML, Rodriguez F, Lopez B, Quesada T, Fenoy FJ, Hernández I 2008 2-Methoxyestradiol attenuates hypertension and coronary vascular remodeling in spontaneously hypertensive rats. Maturitas 61:310-316
20. Zacharia LC, Gogos JA, Karayiorgou M, Jackson EK, Gillespie DG, Barchiesi F, Dubey RK 2003 Methoxyestradiols mediate the antimitogenic effects of 17β-estradiol: direct evidence from catechol- O-methyltransferase-knockout mice. Circulation 108:2974-2978 (Pubitemid 37553565)
21. Barchiesi F, Lucchinetti E, Zaugg M, Ogunshola OO, Wright M, Meyer M, Rosselli M, Schaufelberger S, Gillespie DG, Jackson EK, Dubey RK 2010 Candidate genes and mechanisms for 2-methoxyestradiol- mediated vasoprotection. Hypertension 56:964-972
22. Miller VM 2010 Estrogen metabolomics: a physiologist's perspective. Hypertension 56:816-818
23. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, Karayiorgou M 1998 Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 95:9991-9996 (Pubitemid 28415282)
24. Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML2000 Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques 29: 52:54
25. Kumar A, Lindner V 1997 Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 17:2238-2244 (Pubitemid 28057127)
26. Zacharia LC, Jackson EK, Gillespie DG, Dubey RK 2001 Catecholamines abrogate antimitogenic effects of 2-hydroxyestradiol on human aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21:1745-1750 (Pubitemid 34219777)
27. Dubey RK, Jackson EK, Gillespie DG, Zacharia LC, Imthurn B 2004 Catecholamines block the antimitogenic effect of estradiol on human coronary artery smooth muscle cells. J Clin Endocrinol Metab 89:3922-3931 (Pubitemid 39089120)
28. Billon-Galés A, Fontaine C, Douin-Echinard V, Delpy L, Berges H, Calippe B, Lenfant F, Laurell H, Guéry JC, Gourdy P, Arnal JF 2009 Endothelial estrogen receptor-α plays a crucial role in the atheroprotective action of 17β-estradiol in low-density lipoprotein receptor-deficient mice. Circulation 120:2567-2576
29. Billon-Galés A, Fontaine C, Filipe C, Douin-Echinard V, Fouque MJ, Flouriot G, Gourdy P, Lenfant F, Laurell H, Krust A, Chambon P, Arnal JF 2009 The transactivating function 1 of estrogen receptor α is dispensable for the vasculoprotective actions of 17β-estradiol. Proc Natl Acad Sci USA 106:2053-2058
30. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME 2002 Estrogen receptor-α mediates the protective effects of estrogen against vascular injury. Circ Res 90:1087-1092 (Pubitemid 34627907)
31. Mooberry SL 2003 Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Update 6:355-361 (Pubitemid 38173586)
32. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS 2002 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptorsα and β. Cancer Res 62:3691-3697 (Pubitemid 34728848)
33. Modder UI, Riggs BL, Spelsberg TC, Fraser DG, Atkinson EJ, Arnold R, Khosla S 2004 Dose-response of estrogen on bone versus the uterus in ovariectomized mice. Eur J Endocrinol 151:503-510 (Pubitemid 39430270)
34. Mä nnist ö PT, Kaakkola S 1999 Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593-628
35. Black PH, Garbutt LD 2002 Stress, inflammation and cardiovascular disease. J Psychosom Res 52:1-23 (Pubitemid 34130239)
36. Kukreja RS, Datta BN, Chakravarti RN 1981 Catecholamine-induced aggravation of aortic and coronary atherosclerosis in monkeys. Atherosclerosis 40:291-298 (Pubitemid 11008526)
37. Huotari M, Gogos JA, Karayiorgou M, Koponen O, Forsberg M, Raasmaja A, Hyttinen J, Mä nnist ö PT 2002 Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 15:246-256
38. Haasio K, Huotari M, Nissinen E, Mä nnist ö PT 2003 Tissue histopathology, clinical chemistry and behaviour of adult Comt-genedisrupted mice. J Appl Toxicol 23:213-219
39. Weinshilboum RM, Raymond FA 1977 Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet 29:125-135 (Pubitemid 8070429)
40. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM 1996 Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243-250 (Pubitemid 26226317)
41. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J 1995 Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry (Mosc) 34:4202-4210
42. Palmatier MA, Kang AM, Kidd KK 1999 Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol Psychiatry 46:557-567 (Pubitemid 29370449)
43. Hagen K, Stovner LJ, Skorpen F, Pettersen E, Zwart JA 2007 The impact of the catechol-O-methyltransferase Val158Met polymorphism on survival in the general population-the HUNT study. BMC Med Genet 8:34
44. Voutilainen S, Tuomainen TP, Korhonen M, Mursu J, Virtanen JK, Happonen P, Alfthan G, Erlund I, North KE, Mosher MJ, Kauhanen J, Tiihonen J, Kaplan GA, Salonen JT 2007 Functional COMT Val158Met polymorphism, risk of acute coronary events and serum homocysteine: the Kuopio ischaemic heart disease risk factor study. PLoS One 2:e181
45. Eriksson AL, Skrtic S, Niklason A, Hultén LM, Wiklund O, Hedner T, Ohlsson C 2004 Association between the low activity genotype of catechol-O-methyltransferase and myocardial infarction in a hypertensive population. Eur Heart J 25:386-391 (Pubitemid 38391520)
46. Yamaguchi S, Yamada Y, Metoki N, Yoshida H, Satoh K, Ichihara S, Kato K, Kameyama T, Yokoi K, Matsuo H, Segawa T, Watanabe S, Nozawa Y 2006 Genetic risk for atherothrombotic cerebral infarction in individuals stratified by sex or conventional risk factors for atherosclerosis. Int J Mol Med 18:871-883
47. Casey ML, MacDonald PC 1983 Characterization of catechol-O- methyltransferase activity in human uterine decidua vera tissue. Am J Obstet Gynecol 145:453-457 (Pubitemid 13138132)
48. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, Parry S, Augustin HG, Gattone VH, Folkman J, Strauss JF, Kalluri R 2008 Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 453:1117-1121 (Pubitemid 351871733)